Harold J Burstein1, Christina Lacchetti2, Holly Anderson2, Thomas A Buchholz2, Nancy E Davidson2, Karen E Gelmon2, Sharon H Giordano2, Clifford A Hudis2, Alexander J Solky2, Vered Stearns2, Eric P Winer2, Jennifer J Griggs2. 1. Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI. guidelines@asco.org. 2. Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI.
Abstract
PURPOSE: To update the ASCO adjuvant endocrine therapy guideline based on emerging data concerning the benefits and risks of ovarian suppression in addition to standard adjuvant therapy in premenopausal women with estrogen receptor-positive breast cancer. METHODS: ASCO convened an Update Panel and conducted a systematic review of randomized clinical trials investigating ovarian suppression. RESULTS: Two trials investigating the addition of ovarian suppression to tamoxifen did not show an overall clinical benefit for ovarian suppression. Nonetheless, the addition of ovarian suppression to standard adjuvant therapy with tamoxifen or with an aromatase inhibitor improved disease-free survival and improved freedom from breast cancer and distant recurrence compared with tamoxifen alone among the subset of patients who were at sufficient risk for recurrence such that adjuvant chemotherapy was warranted. Compared with tamoxifen alone, ovarian suppression was associated with a substantial increase in menopausal symptoms, sexual dysfunction, and diminished quality of life. RECOMMENDATIONS: The Panel recommends that higher-risk patients should receive ovarian suppression in addition to adjuvant endocrine therapy, whereas lower-risk patients should not. Women with stage II or III breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression with endocrine therapy. The panel recommends that some women with stage I or II breast cancers at higher risk of recurrence who might consider chemotherapy may also be offered ovarian suppression with endocrine therapy. Women with stage I breast cancers not warranting chemotherapy should not receive ovarian suppression, nor should women with node-negative cancers 1 cm or less. Ovarian suppression may be administered with either tamoxifen or an aromatase inhibitor. Additional information is available at www.asco.org/guidelines/endocrinebreast and www.asco.org/guidelineswiki.
PURPOSE: To update the ASCO adjuvant endocrine therapy guideline based on emerging data concerning the benefits and risks of ovarian suppression in addition to standard adjuvant therapy in premenopausal women with estrogen receptor-positive breast cancer. METHODS:ASCO convened an Update Panel and conducted a systematic review of randomized clinical trials investigating ovarian suppression. RESULTS: Two trials investigating the addition of ovarian suppression to tamoxifen did not show an overall clinical benefit for ovarian suppression. Nonetheless, the addition of ovarian suppression to standard adjuvant therapy with tamoxifen or with an aromatase inhibitor improved disease-free survival and improved freedom from breast cancer and distant recurrence compared with tamoxifen alone among the subset of patients who were at sufficient risk for recurrence such that adjuvant chemotherapy was warranted. Compared with tamoxifen alone, ovarian suppression was associated with a substantial increase in menopausal symptoms, sexual dysfunction, and diminished quality of life. RECOMMENDATIONS: The Panel recommends that higher-risk patients should receive ovarian suppression in addition to adjuvant endocrine therapy, whereas lower-risk patients should not. Women with stage II or III breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression with endocrine therapy. The panel recommends that some women with stage I or II breast cancers at higher risk of recurrence who might consider chemotherapy may also be offered ovarian suppression with endocrine therapy. Women with stage I breast cancers not warranting chemotherapy should not receive ovarian suppression, nor should women with node-negative cancers 1 cm or less. Ovarian suppression may be administered with either tamoxifen or an aromatase inhibitor. Additional information is available at www.asco.org/guidelines/endocrinebreast and www.asco.org/guidelineswiki.
Authors: Tessa G Steenbruggen; Mette S van Ramshorst; Marleen Kok; Sabine C Linn; Carolien H Smorenburg; Gabe S Sonke Journal: Drugs Date: 2017-08 Impact factor: 9.546
Authors: Rajiv P Parikh; Elizabeth B Odom; Liyang Yu; Graham A Colditz; Terence M Myckatyn Journal: Breast Cancer Res Treat Date: 2017-02-09 Impact factor: 4.872
Authors: Rinath Jeselsohn; MacIntosh Cornwell; Matthew Pun; Gilles Buchwalter; Mai Nguyen; Clyde Bango; Ying Huang; Yanan Kuang; Cloud Paweletz; Xiaoyong Fu; Agostina Nardone; Carmine De Angelis; Simone Detre; Andrew Dodson; Hisham Mohammed; Jason S Carroll; Michaela Bowden; Prakash Rao; Henry W Long; Fugen Li; Mitchell Dowsett; Rachel Schiff; Myles Brown Journal: Proc Natl Acad Sci U S A Date: 2017-05-15 Impact factor: 11.205
Authors: Saamir A Hassan; Nicolas Palaskas; Peter Kim; Cezar Iliescu; Juan Lopez-Mattei; Elie Mouhayar; Rohit Mougdil; Kara Thompson; Jose Banchs; Syed Wamique Yusuf Journal: Curr Atheroscler Rep Date: 2018-02-08 Impact factor: 5.113